Neurocrine Biosciencesvs.Regeneron
NBIX vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 3.9× larger than Neurocrine Biosciences by market cap; Regeneron trades at the lower P/E (15.7 vs 26.4); year to date, Neurocrine Biosciences leads (+24.9% vs −13.9%).
Side by side
| NBIX | REGN | |
|---|---|---|
| Market cap | $17.7B | $69.7B |
| Price | $177.11 | $664.52 |
| Today | −1.9% | −0.5% |
| Return YTD | +24.9% | −13.9% |
| Return 1Y | +31.3% | +18.7% |
| P/E | 26.4 | 15.7 |
| P/S | 5.7 | 4.7 |
| P/B | 5.2 | 2.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Neurocrine BiosciencesNBIX
Biopharma focused on neurological and endocrine diseases (Ingrezza).
Full NBIX profile →RegeneronREGN
American biotech company focused on antibody-based medicines in ophthalmology, immunology and oncology.
Full REGN profile →More comparisons in Biotech & innovation
See where NBIX and REGN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →